Enzo Biochem (ENZ) Q2 2025 earnings summary

Executive summary

• Revenue declined 14% year-over-year to $7.3M for the quarter and 17% to $13.5M for the six months, driven by lower demand and timing of large orders, but rose 18% sequentially.

• Gross margin improved to 52% from 49% year-over-year and from 37% sequentially, reflecting a more profitable product mix and cost containment.

• Operating loss narrowed to $1.6M for the quarter and $5.2M for the six months, with the Products segment posting a $0.5M operating profit in Q2 FY25.

• Net loss was $1.5M for the quarter and $4.9M for the six months, both improved from prior year periods; adjusted net loss for Q2 FY25 was $0.97M.

• The company completed the sale of its clinical services business in July 2023 and now operates solely as a life sciences products company.

Financial highlights

• Quarterly revenue: $7.3M (down 14% year-over-year, up 18% sequentially); six-month revenue: $13.5M (down 17%).

• Gross margin: 52% for the quarter, 47% for the six months.

• Operating loss: $1.6M for the quarter, $5.2M for the six months; adjusted EBITDA for Q2 FY25 was $(0.88)M.

• Net loss per share: $(0.03) for the quarter, $(0.09) for the six months; adjusted net loss per share: $(0.02) for Q2 FY25.

• Cash and cash equivalents: $40.3M as of January 31, 2025, down from $52.4M at July 31, 2024.

Outlook and guidance

• Management believes current working capital is sufficient for at least the next twelve months and continues to focus on cost efficiency, product launches, and cash conservation.

• The company is exploring strategic alternatives, including organic growth, acquisitions, joint ventures, or a potential sale to maximize shareholder value.

• Submitted a plan to the NYSE to address market capitalization and stock price deficiencies; stock remains listed pending review.